Skip to main content
. Author manuscript; available in PMC: 2018 Mar 15.
Published in final edited form as: Cancer Res. 2017 Feb 15;77(6):1492–1502. doi: 10.1158/0008-5472.CAN-16-2755

Fig. 6. Aberrant increase of Syk activation and expression is identified in LAM.

Fig. 6

(A) Representative immunohistochemical staining of LAM lungs. From left to right: immunoreactivity for phospho-Syk and total Syk visualized with diaminobenzidine (DAB) is observed in LAM lung nodules. Absence of immunoreactivity with nonimmune IgG in the LAM lung. (n=6 LAM patients). Scale bars: 500 μm (upper panels), 50 μm (lower panels). (B) Serum was collected from 27 LAM patients for a total of 200 visits before (80 visits, Y-axis on the left) and after (120 visits, Y-axis on the right) sirolimus treatment. MCP-1 and VEGF-D were measured in serum using magnetic bead-based multiplex screening assays. Correlation coefficients between levels of MCP-1 and VEGF-D were calculated with Pearson correlation test. (C) Real-time PCR analysis of human VEGF-D mRNA in human peripheral blood mononuclear cells (PBMCs) from healthy volunteers as control (n=16) and LAM patients (n=22). Results were expressed as the fold change relative to healthy control subjects. Data represent means ± SEM. **P < 0.01, by Student’s t test.